Brokerages Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Target Price at $133.75

Zimmer Biomet Holdings, Inc. (NYSE:ZBHGet Free Report) has been assigned an average recommendation of “Hold” from the sixteen analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $133.75.

Several equities analysts recently commented on ZBH shares. Oppenheimer upped their price target on shares of Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Citigroup upped their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. The Goldman Sachs Group began coverage on shares of Zimmer Biomet in a research note on Thursday, May 30th. They issued a “neutral” rating and a $129.00 target price on the stock. Barclays dropped their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research note on Friday, May 31st. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, May 30th.

View Our Latest Research Report on Zimmer Biomet

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds and other institutional investors have recently bought and sold shares of the company. OLD Point Trust & Financial Services N A purchased a new stake in Zimmer Biomet during the fourth quarter valued at approximately $26,000. Crewe Advisors LLC purchased a new stake in Zimmer Biomet during the first quarter valued at approximately $31,000. Ables Iannone Moore & Associates Inc. purchased a new stake in Zimmer Biomet during the fourth quarter valued at approximately $30,000. J.Safra Asset Management Corp lifted its position in Zimmer Biomet by 712.1% during the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 235 shares during the last quarter. Finally, Naples Money Management LLC purchased a new stake in Zimmer Biomet during the fourth quarter valued at approximately $35,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $107.86 on Wednesday. The company has a market capitalization of $22.19 billion, a price-to-earnings ratio of 23.35, a PEG ratio of 1.91 and a beta of 1.02. Zimmer Biomet has a 12 month low of $102.00 and a 12 month high of $147.50. The firm’s 50-day moving average is $116.59 and its 200 day moving average is $121.55. The company has a current ratio of 1.66, a quick ratio of 0.80 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBHGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, beating the consensus estimate of $1.87 by $0.07. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The firm’s revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.89 EPS. Research analysts predict that Zimmer Biomet will post 8.1 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.89%. Zimmer Biomet’s payout ratio is 20.78%.

Zimmer Biomet Company Profile

(Get Free Report

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Read More

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.